Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy

Journal of Immunotherapy

Volumn 38, Issue 2, 2015, Pages 41-53

  Odegard, Jared M ^a,c   Kelley Clarke, Brenna ^a   Tareen, Semih U ^a,f   Campbell, David J ^a   Flynn, Patrick A ^a   Nicolai, Christopher J ^a   Slough, Megan M ^a   Vin, Chintan D ^a   McGowan, Patrick J ^a   Nelson, Lisa T ^b   Ter Meulen, Jan ^a   Dubensky, Thomas W ^a,d   Robbins, Scott H ^a,e  

^a Immune Design   (United States)

^b TRIA Bioscience Corp   (United States)

^c BENAROYA RESEARCH INSTITUTE   (United States)

^d Aduro BioTech Inc   (United States)

^e Juno Therapeutics ^*  (United States)

^f Juno Therapeutics   (United States)

Author keywords

DC SIGN; immunotherapy; lentiviral vector

Indexed keywords

CD209 ANTIGEN; ID VP 02; INTEGRATION DEFICIENT LENTIVIRAL VECTOR; INTERLEUKIN 7 RECEPTOR ALPHA; LENTIVIRUS VECTOR; NUCLEIC ACID; PROTEIN; PROTEIN SIGNR1; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; CANCER VACCINE; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; DC-SPECIFIC ICAM-3 GRABBING NONINTEGRIN; GLYCOPROTEIN; INTERLEUKIN 7 RECEPTOR; INTERLEUKIN-7 RECEPTOR, ALPHA CHAIN; LECTIN; PROTEIN BINDING; VIRAL PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CARCINOMA CELL LINE; CD8+ T LYMPHOCYTE; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG SPECIFICITY; EFFECTOR CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNIZATION; IN VIVO STUDY; INJECTION SITE; LYMPH NODE; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; SINDBIS VIRUS; T LYMPHOCYTE ACTIVATION; VACCINIA VIRUS; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CARCINOMA; COLONIC NEOPLASMS; CYTOTOXICITY; GENE VECTOR; GENETIC ENGINEERING; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LENTIVIRINAE; LYMPHOCYTE ACTIVATION; METABOLISM; PHASE 1 CLINICAL TRIAL (TOPIC); TRANSPLANTATION; TUMOR CELL LINE; VACCINIA; VIROLOGY; VIRUS DNA CELL DNA INTERACTION;

ANIMALS; CANCER VACCINES; CARCINOMA; CD8-POSITIVE T-LYMPHOCYTES; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CLINICAL TRIALS, PHASE I AS TOPIC; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; GENETIC ENGINEERING; GENETIC VECTORS; GLYCOPROTEINS; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ADOPTIVE; LECTINS, C-TYPE; LENTIVIRUS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROTEIN BINDING; RECEPTORS, CELL SURFACE; RECEPTORS, INTERLEUKIN-7; SINDBIS VIRUS; VACCINIA; VACCINIA VIRUS; VIRAL PROTEINS; VIRUS INTEGRATION;

EID: 84922733904     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000067     Document Type: Article

References (27)

1. Mellman I. Dendritic cells: Master regulators of the immune response. Cancer Immunol Res. 2013;1:145-149.
2. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013;39:38-48.
3. Liu MA. Immunologic basis of vaccine vectors. Immunity. 2010;33:504-515.
4. Yang L, Yang H, Rideout K, et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol. 2008;26:326-334.
5. Breckpot K, Emeagi PU, Thielemans K. Lentiviral vectors for anti-tumor immunotherapy. Curr Gene Ther. 2008;8:438-448.
6. Tareen SU, Kelley-Clarke B, Nicolai CJ, et al. Design of a novel integration-deficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cells. Mol Ther. 2014;22:575-587.
7. Miyoshi H, Blomer U, Takahashi M, et al. Development of a self-inactivating lentivirus vector. J Virol. 1998;72:8150-8157.
8. Bayer M, Kantor B, Cockrell A, et al. A large U3 deletion causes increased in vivo expression from a nonintegrating lentiviral vector. Mol Ther. 2008;16:1968-1976.
9. Hrecka K, Hao C, Gierszewska M, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature. 2011;474:658-661.
10. Laguette N, Sobhian B, Casartelli N, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature. 2011;25:654-657, Tareen.
11. Tareen SU, Nicolai CJ, Campbell DJ, et al. A rev-independent gag/pol eliminates detectable psi-gag recombination in lentiviral vectors. Biores Open Access. 2013;2:421-430.
12. Kantor B, Bayer M, Ma H, et al. Notable reduction in illegitimate integration mediated by a PPT-deleted, nonintegrating lentiviral vector. Mol Ther. 2011;19:547-556.
13. Wiskerchen M, Muesing MA. Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells. J Virol. 1995;69:376-386.
14. Kotsopoulou E, Kim VN, Kingsman AJ, et al. A Rev-independent human immunodeficiency virus type 1 (HIV-1)- based vector that exploits a codon-optimized HIV-1 gag-pol gene. J Virol. 2000;74:4839-4852.
15. Wagner R, Graf M, Bieler K, et al. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. Hum Gene Ther. 2000;11:2403-2413.
16. Butler SL, Hansen MS, Bushman. FD. A quantitative assay for HIV DNA integration in vivo. Nat Med. 2001;7: 631-634.
17. Wonderlich J, Shearer G, Livingstone A, Brooks A. Induction and measurement of cytotoxic T lymphocyte activity. Curr Protoc Immunol. 2006, Chapter 3 unit 3.1
18. Powlesland AS, Ward EM, Sadhu SK, et al. Widely divergent biochemical properties of the complete set of mouse DC-SIGN-related proteins. J Biol Chem. 2006;281: 20440-20449.
19. Betts G, Poyntz H, Stylianou E, et al. Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection. PLoS One. 2012;7:e50447.
20. Kaech SM, Tan JT, Wherry EJ, et al. 2003. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol. 2003;4:1191-1198.
21. Obar JJ, Jellison ER, Sheridan BS, et al. Pathogen-induced inflammatory environment controls effector and memory CD8+ T cell differentiation. J Immunol. 2011;187: 4967-4978.
22. Slansky JE, Rattis FM, Boyd LF. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity. 2000;13: 529-538.
23. Brockstedt DG, Giedlin MA, Leong ML, et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci USA. 2004;101:13832-13837.
24. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1-10.
25. Wimmers F, Schreibelt G, Skold AE, et al. Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets. Front Immunol. 2014;5:1-12.
26. Bonifaz LC, Bonnyay DP, Charalambous A, et al. In vivo targeting of antigens to maturing dendritic cells via the DEC- 205 receptor improves T cell vaccination. J Exp Med. 2004; 199:815-824.
27. Dhodapkar MV, Sznol M, Zhao B, et al. Induction of antigenspecific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med. 2014;16:232ra51.